JP2013502204A5 - - Google Patents

Download PDF

Info

Publication number
JP2013502204A5
JP2013502204A5 JP2012525000A JP2012525000A JP2013502204A5 JP 2013502204 A5 JP2013502204 A5 JP 2013502204A5 JP 2012525000 A JP2012525000 A JP 2012525000A JP 2012525000 A JP2012525000 A JP 2012525000A JP 2013502204 A5 JP2013502204 A5 JP 2013502204A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr3
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012525000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013502204A (ja
JP5936067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2010/001070 external-priority patent/WO2011020155A1/en
Publication of JP2013502204A publication Critical patent/JP2013502204A/ja
Publication of JP2013502204A5 publication Critical patent/JP2013502204A5/ja
Application granted granted Critical
Publication of JP5936067B2 publication Critical patent/JP5936067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012525000A 2009-08-20 2010-08-20 抗p2x7受容体抗体およびその断片 Active JP5936067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009903928 2009-08-20
AU2009903928A AU2009903928A0 (en) 2009-08-20 Anti P2X7 receptor antibodies and fragments thereof
PCT/AU2010/001070 WO2011020155A1 (en) 2009-08-20 2010-08-20 Anti p2x7 receptor antibodies and fragments thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016019816A Division JP6224141B2 (ja) 2009-08-20 2016-02-04 抗p2x7受容体抗体およびその断片

Publications (3)

Publication Number Publication Date
JP2013502204A JP2013502204A (ja) 2013-01-24
JP2013502204A5 true JP2013502204A5 (https=) 2013-10-03
JP5936067B2 JP5936067B2 (ja) 2016-06-15

Family

ID=43606479

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012525000A Active JP5936067B2 (ja) 2009-08-20 2010-08-20 抗p2x7受容体抗体およびその断片
JP2016019816A Active JP6224141B2 (ja) 2009-08-20 2016-02-04 抗p2x7受容体抗体およびその断片
JP2017193317A Active JP6417016B2 (ja) 2009-08-20 2017-10-03 抗p2x7受容体抗体およびその断片

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016019816A Active JP6224141B2 (ja) 2009-08-20 2016-02-04 抗p2x7受容体抗体およびその断片
JP2017193317A Active JP6417016B2 (ja) 2009-08-20 2017-10-03 抗p2x7受容体抗体およびその断片

Country Status (5)

Country Link
US (6) US9127059B2 (https=)
EP (3) EP2467404B1 (https=)
JP (3) JP5936067B2 (https=)
ES (3) ES2704711T3 (https=)
WO (1) WO2011020155A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性p2x7レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
GB201522541D0 (en) * 2015-12-21 2016-02-03 Inst Research In Biomedicine Compositions
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威(英国)有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
FR3084365B1 (fr) * 2018-07-27 2020-10-23 Cisbio Bioassays Anticorps a domaine unique qui se lient a la proteine g alpha
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
EP4304610A4 (en) * 2021-03-11 2025-03-05 Biosceptre (Aust) Pty Ltd Novel cell therapy system
US20240368282A1 (en) * 2021-09-01 2024-11-07 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity
WO2025042968A1 (en) * 2023-08-22 2025-02-27 Integral Molecular, Inc. Compositions and methods related to chicken recombinant heavy-chain only antibodies

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトP2x4レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性p2x7レセプター抗体、癌及びその他の容態の診断及び処置
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP5364378B2 (ja) * 2005-11-09 2013-12-11 アボット・ラボラトリーズ ヒトbnp免疫特異的抗体
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) * 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Similar Documents

Publication Publication Date Title
JP2013502204A5 (https=)
JP2009225799A5 (https=)
JP2014526898A5 (https=)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2010511388A5 (https=)
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP2010502207A5 (https=)
JP2013538057A5 (https=)
JP2017052784A5 (https=)
JP2014511179A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2012116856A5 (https=)
JP2012526542A5 (https=)
JP2014205674A5 (https=)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2011173884A5 (https=)
JP2013506428A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2010536384A5 (https=)
JP2014512809A5 (https=)
JP2010526028A5 (https=)
JP2012010714A5 (https=)
RU2020129387A (ru) Антитела к pd-1 собак
HRP20160632T1 (hr) Vezivne molekule specifične za rsv i sredstva za njihovu proizvodnju
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use